The DLX6 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout population designed for targeted disruption of the DLX6 gene within the near?haploid HAP1 human cell line. This product delivers a genetically mixed pool of cells harboring loss?of?function mutations, enabling gene?disruption studies without clonal isolation. The polyclonal format is particularly well?suited for pooled functional genomics approaches, including CRISPR?based screens and bulk transcriptomic analyses, where population?level phenotypic readouts are required. By providing a reproducible source of DLX6?null cells, this tool supports systematic dissection of gene function in a leukemic cell background.
HAP1 is a pseudodiploid, near?haploid human cell line originally derived from the KBM?7 chronic myeloid leukemia (CML) line, exhibiting fibroblast?like morphology and adherent growth. The near?haploid karyotype reduces gene copy number to a single allele for most genes, minimizing genetic redundancy and simplifying loss?of?function interpretation. This characteristic makes HAP1 an ideal host for high?throughput CRISPR screening and detailed biochemical assays, where penetrant phenotypes are desirable. The cell line retains key signaling pathways relevant to hematopoietic and cancer biology, offering a versatile platform for investigating transcription factor networks in a leukemic context.
DLX6 encodes a homeobox transcription factor essential for craniofacial and limb morphogenesis. Mechanistically, DLX6 forms functional heterodimers with DLX5 and participates in autoregulatory loops with MSX1, MSX2, and BMP4, integrating upstream signals from BMP4, FGF8, and WNT ligands. DLX6 transcriptionally regulates downstream effectors such as MSX1, MSX2, BMP4, and ALX4, thereby governing the expression of genes pivotal for pattern formation and cell fate determination. Additional interacting partners, including DLX2, further expand the combinatorial complexity of DLX6?mediated gene regulation, positioning DLX6 at the nexus of multiple developmental signaling cascades.
Although DLX6 is predominantly characterized in embryonic development, aberrant expression has been documented in certain malignancies, and the HAP1 model offers a controlled system to explore DLX6 functions in a CML?derived background. The polyclonal DLX6?knockout cells eliminate the dominant functional allele, enabling researchers to assess consequences of complete gene disruption in a near?haploid environment. This configuration is advantageous for synthetic lethality screens, drug?response assays, and complementation experiments where reintroduction of wild?type or mutant DLX6 can be precisely evaluated without interference from endogenous gene copies.
Investigators can employ these polyclonal knockout cells in a range of downstream applications, including RNA?seq transcriptome profiling to identify differentially expressed targets upon DLX6 loss, and ChIP?seq to map genomic binding sites when re?expressing tagged DLX6. Co?immunoprecipitation and immunofluorescence assays can probe protein?protein interactions with DLX5 and MSX family members, while RT?qPCR quantifies regulation of downstream mediators. The cells are also compatible with differentiation protocols and arrayed CRISPR modifier screens to uncover genetic interactions relevant to craniofacial disorders or leukemic progression. For technical inquiries or to request a consultation, please contact Ascent Research.
